148 -4 (78) 2025 - Kamolova L.Y. - OVARIAN HYPERSTIMULATION SYNDROME

OVARIAN HYPERSTIMULATION SYNDROME

Kamolova L.Y. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

This article is devoted to statistics, the most common causes, clinical signs of ovarian hyperstimulation syndrome in Uzbekistan, as well as modern diagnostic, treatment and prevention measures, and is based on the clinical standard of the Republic of Uzbekistan (compiled on the recommendation of the World Health Organization).

Key words: ascites, intra-abdominal hypertension, assisted reproductive technologies, respiratory failure, laparacentesis, acute respiratory distress syndrome, multiple organ failure.

First page

829

Last page

836

For citation:Kamolova L.Y. - OVARIAN HYPERSTIMULATION SYNDROME//New Day in Medicine 4(78)2025 829-836 https://newdayworldmedicine.com/en/new_day_medicine/4-78-2025

List of References

  1. Naredi N, Talwar P, Sandeep K. VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status. Med J Armed Forces India. 2014;70:58–63. doi: 10.1016/j.mjafi.2012.03.005. [ PMC Free Article] [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Herr D, Bekes I, Wulff C. Local Renin-Angiotensin system in the reproductive system. Front Endocrinol (Lausanne) 2013;4:58–63. doi: 10.3389/fendo.2013.00150. [ PMC Free Article] [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Mathur RS, Tan BK. British Fertility Society Policy and Practice Committee: Prevention of ovarian hyperstimulation syndrome. Hum Fertil (Camb) 2014;17:257–68. doi: 10.3109/14647273.2014.961745. [DOI] [PubMed] [Google Scholar]
  4. Lamazou F, Legouez A, Letouzey V, Grynberg M, Deffieux X, Trichot C, et al. [Ovarian hyperstimulation syndrome: Pathophysiology, risk factors, prevention, diagnosis and treatment] J Gynecol Obstet Biol Reprod (Paris) 2011;40:593–611. doi: 10.1016/j.jgyn.2011.06.008. [DOI] [PubMed] [Google Scholar]
  5. El-Faissal Y. Approaches to complete prevention of OHSS. Middle East Fertil Soc J. 2014;19:13– 5. [Google Scholar]
  6. Franik S, Kremer JA, Nelen WL, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014:CD010287. doi: 10.1002/14651858.CD010287.pub2. [DOI] [PubMed] [Google Scholar]
  7. Castillo JC, Humaidan P, Bernabeu R. Pharmaceutical options for triggering of final oocyte maturation in ART. Biomed Res Int. 2014;2014:580171. doi: 10.1155/2014/580171. [ PMC Free Article] [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chen X, Chen SL, He YX, Ye DS. Minimum dose of hCG to trigger final oocyte maturation and prevent OHSS in a long GnRHa protocol. J Huazhong Univ Sci Technolog Med Sci. 2013;33:133–6. doi: 10.1007/s11596-013-1085-z. [DOI] [PubMed] [Google Scholar]
  9. Youssef MA, Al-Inany HG, Aboulghar M, Mansour R, Abou-Setta AM. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSIcycles. Cochrane Database Syst Rev. 2011:CD003719. doi: 10.1002/14651858.CD003719.pub3. [DOI] [PubMed] [Google Scholar]
  10. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. doi: 10.1002/14651858.CD001750.pub2. [DOI] [PubMed] [Google Scholar]
  11. Xing W, Lin H, Li Y, Yang D, Wang W, Zhang Q. Is the GnRH Antagonist Protocol Effective at Preventing OHSS for Potentially High Responders Undergoing IVF/ICSI? . PLoS One . 2015;10:e0140286. doi: 10.1371/journal.pone.0140286. [ PMC Free Article] [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hershko Klement A, Berkovitz A, Wiser A, Gonen O, Amichay K, Cohen I, et al. GnRH-antagonist programming versus GnRH agonist protocol: A randomized trial. Eur J Obstet Gynecol Reprod Biol. 2015;185:170–3. doi: 10.1016/j.ejogrb.2014.12.021. [DOI] [PubMed] [Google Scholar]
  13. D’Angelo A, Brown J, Amso NN. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2011:CD002811. doi: 10.1002/14651858.CD002811.pub3. [DOI] [PubMed] [Google Scholar]
  14. Naredi N, Karunakaran S. Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyperstimulation syndrome. J Hum Reprod Sci. 2013;6:248–52. doi: 10.4103/0974-1208.126293. [ PMC Free Article] [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tang H, Hunter T, Hu Y, Zhai SD, Sheng X, Hart RJ. Cabergoline for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev. 2012:CD008605. doi: 10.1002/14651858.CD008605.pub2. [DOI] [PubMed] [Google Scholar]

    file

    download